Mga Batayang Estadistika
| LEI | 549300VWUGH3220TG273 |
| CIK | 1359931 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Protara Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 11, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Protara Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity 2024 Equit |
|
| August 11, 2025 |
Exhibit 10.2 PROTARA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Protara Therapeutics, Inc. (the “Company”) and William Conkling (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”) as of June 2, 2025 (the “Effective Date). WHEREAS, the Parties desire to enter i |
|
| August 11, 2025 |
As filed with the Securities and Exchange Commission on August 11, 2025 As filed with the Securities and Exchange Commission on August 11, 2025 Registration No. |
|
| August 11, 2025 |
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update ● Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 ● Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on par |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| August 11, 2025 |
2024 Equity Incentive Plan, as Amended. Exhibit 10.3 ProtARA Therapeutics, Inc. 2024 Equity Incentive Plan, AS AMENDED 1. Purpose This Plan is intended to provide incentives that will attract, retain and motivate highly competent officers, directors, employees, consultants and advisors to promote the success of the Company’s business and align employees’ interests with stockholders’ interests. The Plan is intended to be an incentive sto |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| May 8, 2025 |
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update ● Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC ● Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 ● Dosing of first patient i |
|
| May 8, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.7 Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Protara Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service ef |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| May 8, 2025 |
Exhibit 10.6 PROTARA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Protara Therapeutics, Inc. (the “Company”) and Leonardo Viana Nicacio (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”) as of April 15, 2025 (the “Effective Date). WHEREAS, the Parties desire to |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2025 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| April 28, 2025 |
21,686,760 shares of Common Stock Filed Pursuant to Rule 424(b)(7) Registration No. 333-279067 PROSPECTUS SUPPLEMENT (To Prospectus dated May 9, 2024) 21,686,760 shares of Common Stock Unless otherwise stated, all references in this prospectus supplement to “we,” “us,” “our,” “Protara,” the “Company” and similar designations refer to Protara Therapeutics, Inc. This prospectus supplement updates the prospectus dated May 9, 2024, re |
|
| April 28, 2025 |
Interim Data Presentation from the American Urological Association Annual Meeting April 2025 Exhibit 99.2 Interim Data Presentation from the American Urological Association Annual Meeting April 2025 Forward Looking Statements 2 Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Protara may, in some cases, use terms such as “predicts,” “believ |
|
| April 28, 2025 |
Exhibit 99.3 SAFETY TABLE 4. FAVORABLE AND WELL - TOLERATED SAFETY PROFILE ACROSS BCG EXPOSURES Grade 4/5 Grade 3 Grade 2 Grade 1 Any Grade N=43 0 (0) 8 (19) 13 (30) 26 (60) 32 (74) Participants with TEAEs, n (%) 0 (0) 0 (0) 1 (2) 12 (28) 13 (30) Participants with Related TEAEs, n (%) 0 (0) 6 (14) 2 (5) 0 (0) 6 (14) Participants with Serious TEAEs, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Participants |
|
| April 28, 2025 |
Exhibit 99.1 Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC ● TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients ● TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month la |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
Exhibit 19.1 PROTARA THERAPEUTICS, INC. INSIDER TRADING POLICY Persons Covered This Insider Trading Policy of Protara Therapeutics, Inc. (the “Company”) applies to all directors, officers, employees and certain other consultants of the Company and any subsidiaries as the Chief Executive Officer, the Chief Financial Officer/principal financial officer or General Counsel may designate from time to t |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| March 5, 2025 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Proteon Securities Corp. Massachusetts Proteon International Holdings, Inc. Delaware Proteon Bermuda Limited Bermuda Proteon Ireland Limited Ireland ArTara Subsidiary, Inc. Delaware All subsidiaries are 100% owned. |
|
| March 5, 2025 |
First Certificate of Amendment to Inducement Plan of the Registrant dated March 3, 2025. Exhibit 10.36 First Certificate of Amendment to ArTara Therapeutics, Inc. Inducement Plan Protara Therapeutics, Inc., formerly known as ArTara Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify: First: Pursuant to the Charter of the Compensation Committee (the “Committee”) of the Board of Directors of the Company, t |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therap |
|
| March 5, 2025 |
Exhibit 99.1 Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update ● Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025 ● Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dep |
|
| March 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Protara Therapeutics, Inc. |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110245.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| February 12, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p25-0263exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of fi |
|
| January 13, 2025 |
Exhibit 99.1 CORPORATE PRESENTATION January 2025 FORWARD LOOKING STATEMENTS 2 © 2025 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Protara may, in some cases, use terms such as |
|
| January 13, 2025 |
Exhibit 99.2 Protara Highlights Recent Updates and Anticipated 2025 Milestones Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month evaluable NMIBC patients in ADVANCED-2 trial expected in mid-2025; Results from a futility analysis of approximately 25 six |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| December 17, 2024 |
EX-99.1 2 ex991to13g12927tara121724.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated December 17, 2024 with respect to the Common Stock, par value $0.001 per share, of Protara Therapeutics, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersign |
|
| December 17, 2024 |
SC 13G 1 sc13g12927tara12172024.htm THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Protara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share ( |
|
| December 11, 2024 |
Protara Announces Proposed Public Offering Exhibit 99.1 Protara Announces Proposed Public Offering NEW YORK, December 9, 2024 (GLOBE NEWSWIRE) - Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing common stock |
|
| December 11, 2024 |
Exhibit 1.1 Execution Version Protara Therapeutics, Inc. 13,690,000 Shares of Common Stock Pre-Funded Warrants to Purchase 2,325,372 Shares of Common Stock UNDERWRITING AGREEMENT December 9, 2024 TD Securities (USA) LLC Cantor Fitzgerald & Co. LifeSci Capital LLC As Representatives of the several Underwriters c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 c/o Cantor Fitzg |
|
| December 11, 2024 |
Protara Announces Closing of $100 Million Public Offering Exhibit 99.3 Protara Announces Closing of $100 Million Public Offering NEW YORK, December 11, 2024 (GLOBE NEWSWIRE) - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,690,000 shares of its common stock at a public offering price |
|
| December 11, 2024 |
Protara Announces Pricing of $100 Million Public Offering Exhibit 99.2 Protara Announces Pricing of $100 Million Public Offering NEW YORK, December 9, 2024 (GLOBE NEWSWIRE) - Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,690,000 shares of its common stock at a price to t |
|
| December 11, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275290 PROSPECTUS SUPPLEMENT (To Prospectus dated November 14, 2023) 13,690,000 Shares of Common Stock and 2,325,372 Pre-Funded Warrants to Purchase Shares of Common Stock We are offering 13,690,000 shares of our common stock, par value $0.001 per share, in this offering and, in lieu of common stock to certain investors that so choose, pre-fund |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| December 11, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: December [ ], 2024 PROTARA THERAPEUTICS, INC. Protara Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| December 9, 2024 |
SUBJECT TO COMPLETION, DATED DECEMBER 9, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-275290 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| December 5, 2024 |
Exhibit 99.2 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC ● TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures ● 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients ● 64% six-m |
|
| December 5, 2024 |
Exhibit 99.3 Presented at the 2024 Annual Meeting of the Society of Urologic Oncology, December 4 - C, 2024; Dallas, Texas ADVANCED - 2: Phase 2 Open - label Study to Evaluate Safety and Anti - tumor Activity of Intravesical Instillation of TARA - 002 in Adults with High - grade Non - muscle Invasive Bladder Cancer Brian Mazzarella 1 , Gautam Jayram 2 , Neal Shore 3 , Jacqueline Zummo 4 , Wei Sun |
|
| December 5, 2024 |
Exhibit 99.1 ADVANCED - 2 TRIAL INTERIM RESULTS December 2024 FORWARD LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “des |
|
| November 18, 2024 |
TARA / Protara Therapeutics, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365U107 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Autho |
|
| November 14, 2024 |
SC 13G 1 p24-3058sc13g.htm PROTARA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365U107 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) |
|
| November 14, 2024 |
TARA / Protara Therapeutics, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm2428264d5sc13ga.htm SC 13G/A CUSIP No: 74365U107 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| November 12, 2024 |
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update Exhibit 99.1 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update · On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024 · Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mid-2025 · In pediatric LMs patients, TARA-002 demonstrated encouraging results and w |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2024 |
Exhibit 99.2 PROTARA THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose and History The purpose of the Plan is to give Employees wishing to do so a convenient means of purchasing Common Stock of the Company through payroll deductions. The Company believes that ownership of Common Stock by Employees will foster greater Employee interest in the Company’s growth and development. The Plan |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Protara Therapeutics, Inc. |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| August 6, 2024 |
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update Exhibit 99.1 Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update ● On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024 ● Expect to dose first patient in pivotal trial for IV Choline Chloride in Q1 2025 ● Current cash resources are approximately $90 million, including net proceeds f |
|
| August 6, 2024 |
Exhibit 99.3 [Letterhead of Protara Therapeutics, Inc.] PROTARA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT THIS AGREEMENT dated as of the Grant Notice date, between Protara Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and the individual identified in paragraph 1 below, currently residing at the address set out at the |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
Exhibit 99.1 ProtARA Therapeutics, Inc. 2024 Equity Incentive Plan 1. Purpose This Plan is intended to provide incentives that will attract, retain and motivate highly competent officers, directors, employees, consultants and advisors to promote the success of the Company’s business and align employees’ interests with stockholders’ interests. The Plan is intended to be an incentive stock option pl |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2024 |
21,686,760 shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279067 PROSPECTUS 21,686,760 shares of Common Stock This prospectus covers the resale, from time to time, by the selling stockholders identified in this prospectus, or, the selling stockholders of up to 21,686,760 shares of our common stock, par value $0.001 per share, (“common stock”) consisting of (i) 9,143,380 shares of common stock held by |
|
| May 7, 2024 |
Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor New York, NY 10010 Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor New York, NY 10010 May 7, 2024 VIA EDGAR U.S. Securities and Exchange Commission, Division of Corporation Finance, Office of Life Sciences, 100 F. Street, N.E., Washington, D.C. 20549. Re: Protara Therapeutics, Inc. Registration Statement on Form S-3 Filed May 2, 2024 File No. 333-279067 Request for Acceleration of Effective Date Ladies |
|
| May 2, 2024 |
Exhibit 10.2 January 24, 2024 Jacqueline Zummo, Ph.D. c/o Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Via E-Mail Re: Retention Award Opportunity Dear Jackie: Recognizing the vital role you pay at Protara Therapeutics, Inc. (the “Company”) and acknowledging the importance of your contributions to the Company over the course of the next year, the Company is pleased |
|
| May 2, 2024 |
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update ● Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC ● Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 ● Reached alignment with FDA on registrational path f |
|
| May 2, 2024 |
As filed with the Securities and Exchange Commission on May 2, 2024 As filed with the Securities and Exchange Commission on May 2, 2024 Registration No. |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| May 2, 2024 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Protara Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy for his or |
|
| May 2, 2024 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Protara Therapeutics, Inc. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 25, 2024 |
TARA / Protara Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365U107 (CUSIP Number) April 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| April 22, 2024 |
EX-99.1 2 tm2412383d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Protara Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 19 |
|
| April 22, 2024 |
TARA / Protara Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 74365U107 |
|
| April 9, 2024 |
TARA / Protara Therapeutics, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 74365U107 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74365U107 (CUSIP Nu |
|
| April 5, 2024 |
Exhibit 99.4 CORPORATE PRESENTATION March 2024 FORWARD LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estima |
|
| April 5, 2024 |
Exhibit 99.1 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition ● New development pathway significantly expands addressable patient population for IV Choline Chloride ● IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the |
|
| April 5, 2024 |
Exhibit 99.3 Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026 NEW YORK, April 5, 2024 – Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today anno |
|
| April 5, 2024 |
EXHIBIT 10.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of April 5, 2024 by and among Protara Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and the P |
|
| April 5, 2024 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made and entered into as of April 5, 2024 (the “Effective Date”) by and among Protara Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on the signature pages hereto, severally and not jointly (each a “Purchaser” and together the “Purchasers”). Certain terms used and no |
|
| April 5, 2024 |
Exhibit 10.3 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR A V |
|
| April 5, 2024 |
Exhibit 10.2 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR A V |
|
| April 5, 2024 |
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC Exhibit 99.2 Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC ● TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive/Experienced patients in ongoing NMIBC program ● TARA-002 demonstrated a complete response rate of 63% at three months in CIS-only patients in ongoing NMIBC program ● TARA-002 demonstrated a favorabl |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| March 18, 2024 |
Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Jathin Bandari, M.D. (“Employee”) and Protara Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee has been employed by the Company; WHEREAS, Employee signed an Executiv |
|
| March 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Protara Therapeutics, Inc. |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therap |
|
| March 13, 2024 |
Exhibit 99.1 Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update ● Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024 ● Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS expected in 2H 2024 ● Cash, cash equi |
|
| March 13, 2024 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Proteon Securities Corp. Massachusetts Proteon International Holdings, Inc. Delaware Proteon Bermuda Limited Bermuda Proteon Ireland Limited Ireland ArTara Subsidiary, Inc. Delaware All subsidiaries are 100% owned. |
|
| March 13, 2024 |
Executive Compensation Clawback Policy. Exhibit 97.1 PROTARA THERAPEUTICS, INC. CLAWBACK POLICY: RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION I. BACKGROUND Protara Therapeutics, Inc. (the “Company”) has adopted this Policy Regarding the Recovery of Erroneously Awarded Incentive-Based Compensation (this “Policy”) to provide for the recovery or “clawback” of excess Incentive-Based Compensation earned by current or former E |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2024 |
EX-99.A 2 ss3005745ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 2 to the Statement on Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of Protara Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of R |
|
| February 14, 2024 |
TARA / Protara Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 ss3005745sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74365U107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State |
|
| November 9, 2023 |
Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor New York, NY 10010 Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor New York, NY 10010 November 9, 2023 VIA EDGAR U.S. Securities and Exchange Commission, Division of Corporation Finance, Office of Life Sciences, 100 F. Street, N.E., Washington, D.C. 20549. Re: Protara Therapeutics, Inc. Registration Statement on Form S-3 Filed November 3, 2023 File No. 333-275290 Request for Acceleration of Effective D |
|
| November 3, 2023 |
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update Exhibit 99.1 Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update ● Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24 ● Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS ● Company initiated Phase 2 trial of TARA-0 |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 3, 2023 As filed with the Securities and Exchange Commission on November 3, 2023 Registration No. |
|
| November 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| November 3, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Protara Therapeutics, Inc. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| August 3, 2023 |
Exhibit 10.1 PROTARA THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Protara Therapeutics, Inc. (the “Company”), and Patrick Fabbio (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”) as of June 1, 2023. WHEREAS, Executive |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| August 3, 2023 |
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update Exhibit 99.1 Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update ● Dosing is progressing on schedule in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24 ● Company plans to commence dosing in ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS in 4Q23 ● Company |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2023 |
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update Exhibit 99.1 Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update ● Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trial ● Company plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and BCG-unresponsive CIS patients in 2H23 ● Regulatory clearance received from FDA to commence Phase 2 trial o |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| May 2, 2023 |
Exhibit 99.1 Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations ● STARBORN-1 trial leverages data from TARA-002 predecessor therapy OK-432, which is approved and has treated thousands of pediatric patients with Lymphatic Malformations in Japan and Taiwan as well as over 500 patients in a co |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| April 28, 2023 |
Exhibit 99.1 Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development ● Favorable tolerability observed in patients with NMIBC treated with TARA-002 in ADVANCED-1 trial · Anti-tumor activity was observed in all three evaluable patients with CIS, including one heavily pre-tre |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| March 8, 2023 |
Exhibit 10.17 PROTARA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Protara Therapeutics, Inc. (the “Company”), and Patrick Fabbio (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”) as of January 5, 2023, and shall become effective on Executive’s commencement of |
|
| March 8, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Protara Therapeutics, Inc. |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| March 8, 2023 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Proteon Securities Corp. Massachusetts Proteon International Holdings, Inc. Delaware Proteon Bermuda Limited Bermuda Proteon Ireland Limited Ireland ArTara Subsidiary, Inc. Delaware All subsidiaries are 100% owned. |
|
| March 8, 2023 |
As filed with the Securities and Exchange Commission on March 8, 2023 As filed with the Securities and Exchange Commission on March 8, 2023 Registration No. |
|
| March 8, 2023 |
Exhibit 3.6 THIS COMPOSITE CERTIFICATE OF INCORPORATION OF PROTARA THERAPEUTICS, INC. REFLECTS THE PROVISIONS OF ITS SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AS AMENDED AND RESTATED ON OCTOBER 27, 2014, AND ALL AMENDMENTS THERETO FILED WITH THE DELAWARE SECRETARY OF STATE THEREAFTER, BUT IS NOT AN AMENDMENT AND/OR RESTATEMENT THEREOF. COMPOSITE CERTIFICATE OF INCORPORATION OF PROTAR |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therap |
|
| March 8, 2023 |
Exhibit 99.1 Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected in 2Q23 – - Start up Activities for Phase 2 Trial of TARA-002 in Lymphatic Malformations Underway; Trial Initiation Expected 2H23 - - Cash, Cash Equi |
|
| February 14, 2023 |
TARA / ArTara Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss1758608sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Protara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74365U107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| February 14, 2023 |
EX-99 2 ss1758608ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of Protara Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| January 30, 2023 |
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer Exhibit 99.1 Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer NEW YORK, January 30, 2023 – Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January 30, 2023. Mr. Fabbio mos |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| January 5, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commiss |
|
| January 5, 2023 |
Exhibit 99.1 CORPORATE PRESENTATION January 2023 FORWARD LOOKING STATEMENTS 2 ? 2023 Protara Therapeutics. All Rights Reserved ? Do Not Copy or Distribute Statements contained in this press release regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| November 3, 2022 |
Exhibit 99.1 Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview - Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration, Phase 2 Study of TARA-002 in Lymphatic Malformations Expected to Initiate in 2023 - - Strong Cash, Ca |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| August 9, 2022 |
Exhibit 99.1 Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview - Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - Strong Cash, Cash Equivalents and Investments Position of $112.8M as of June 30, 2022 Expected to Fund Operations into Mid-2024 - NEW YORK, August 9, 2022 ? Protara Therapeu |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| June 21, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Blaine Davis (?Employee?) and Protara Therapeutics, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS WHEREAS, Employee has been employed by the Company; WHEREAS, Employee signed an Executive Employment Agreement |
|
| June 21, 2022 |
Protara Therapeutics Announces Departure of Chief Financial Officer Exhibit 99.1 Protara Therapeutics Announces Departure of Chief Financial Officer New York, June 21, 2022 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that Blaine Davis, Chief Financial Officer (CFO), has informed the Company that he will be leaving to pursue other opportuniti |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2022 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Protara Therapeutics, Inc. (the “Company”), and Jathin Bandari(“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), effective as of January 10, 2022 (the “Effective Date”). WHEREAS, the Company and Executive desire to enter |
|
| May 5, 2022 |
Exhibit 99.1 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview - Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents and Investments Position of $119M as of March 31, 2022 Expected to Fund Operations into Mid-2024 - NEW YORK, May 5, 2022 ? Protara Therapeuti |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2022 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 PROTARA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Protara Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non- |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 9, 2022 |
As filed with the Securities and Exchange Commission on March 9, 2022 S-8 1 ea156646-s8protaratherap.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March 9, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 20-4580525 (State or o |
|
| March 9, 2022 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Proteon Securities Corp. Massachusetts Proteon International Holdings, Inc. Delaware Proteon Bermuda Limited Bermuda Proteon Ireland Limited Ireland ArTara Subsidiary, Inc. Delaware All subsidiaries are 100% owned. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therap |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Protara Therapeutics, Inc. |
|
| March 9, 2022 |
Exhibit 99.1 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview - Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, Mar 9, 2022 ? Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage comp |
|
| March 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| February 15, 2022 |
TARA / ArTara Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74365U 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 15, 2022 |
TARA / ArTara Therapeutics, Inc. / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
TARA / ArTara Therapeutics, Inc. / Ikarian Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* PROTARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365U107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
JOINT FILING AGREEMENT February 14, 2022 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a |
|
| February 11, 2022 |
CUSIP No. 74365U107 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, $0.001 par value per share, of Protara Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| February 11, 2022 |
TARA / ArTara Therapeutics, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Protara Therapeutics, Inc. |
|
| January 10, 2022 |
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer Exhibit 99.1 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer NEW YORK, January 10, 2022 ? Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urol |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| November 4, 2021 |
Exhibit 99.1 Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview ? TARA-002 Confirmatory Large-Scale GMP Comparability Complete ? ? U.S. FDA Cleared the Company?s IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End ? ? Strong Cash, Cash Equivalents, and Marketable Debt Securities of $138.4M as of September 30, 20 |
|
| October 18, 2021 |
Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?) by and between Protara Therapeutics, Inc. (?Client?) and Mart?n Sebastian Olivo, M.D., an individual (?Consultant?) is effective as of October 16, 2021 (the ?Effective Date?). RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Consultant to provide suc |
|
| October 18, 2021 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Mart?n Sebastian Olivo, M.D. (?Employee?) and Protara Therapeutics, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an Executive Employment |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| October 12, 2021 |
Exhibit 99.2 Corporate Presentation October 2021 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as ?predicts,? ?believes,? ?potential,? ?proposed,? ?continue,? ?designed,? ?estim |
|
| October 12, 2021 |
Exhibit 99.1 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End - - IND Application Included Submission of Confirmatory Large-Scale GMP Comparability Data - New York, October 12, 2021 ? Protara Therapeutics, Inc. (Nasdaq: TARA), a |
|
| October 12, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| August 5, 2021 |
Exhibit 99.1 Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview - Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to be Completed by Year-End? - Company Plans to Engage with FDA to Determine Clinical Trial Design fo |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| June 10, 2021 |
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors Exhibit 99.1 Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors NEW YORK, June 10, 2021 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Board of Directors. Dr. Huang, an exp |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| May 6, 2021 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into by and between Protara Therapeutics, Inc. (the ?Company?), and Martin Sebastian Olivo, M.D. (?Executive?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?), effective as of April 19, 2021 (the ?Effective Date?). WHEREAS, the Company and Executive des |
|
| May 6, 2021 |
Restated Non-Employee Director Compensation Policy. Exhibit 10.1 Protara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Protara Therapeutics, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Amended and Restated Non- |
|
| April 27, 2021 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant S Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 23, 2021 |
Exhibit 99.2 Corporate Presentation April 2021 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as ?predicts,? ?believes,? ?potential,? ?proposed,? ?continue,? ?designed,? ?estimat |
|
| April 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| April 23, 2021 |
Exhibit 99.1 Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations NEW YORK, April 23, 2021 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the |
|
| April 19, 2021 |
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer Exhibit 99.1 Protara Therapeutics Announces Appointment of Mart?n Sebastian Olivo, M.D. as Chief Medical Officer NEW YORK, April 19, 2021 ? Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Mart?n Sebastian Olivo, M.D. as Chief Medical |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| March 17, 2021 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| March 17, 2021 |
Letter dated March 17, 2021 from Marcum LLP to the Securities and Exchange Commission. Exhibit 16.1 March 17, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Protara Therapeutics, Inc. under Item 4.01 of its Form 8-K dated March 12, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Protara Therapeutics, Inc. |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Proteon Securities Corp. Massachusetts Proteon International Holdings, Inc. Delaware Proteon Bermuda Limited Bermuda Proteon Ireland Limited Ireland ArTara Subsidiary, Inc. Delaware All subsidiaries are 100% owned. |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 PROTARA THERAP |
|
| March 11, 2021 |
Exhibit 10.25 ?CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.? Execution Version 345 PAS HOLDING LLC, Landlord, TO PROTARA THERAPEUTICS INC., Tenant LEASE Premises at: 345 Park Avenue South New York, New York TABLE OF CONTENTS PAGE ARTICLE 1 BASIC LEASE |
|
| March 11, 2021 |
Exhibit 4.2 DESCRIPTION OF COMMON STOCK The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this ?Description of Common Stock,? you should refer to our sixth amended and restated certificate of incorporation, as am |
|
| March 3, 2021 |
Protara Therapeutics, Inc. Corporate Presentation, March 2021. Exhibit 99.1 |
|
| March 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74365U 107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PROTARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365U107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 11, 2021 |
EX-99.1 2 ea135113ex99-1protara.htm PROTARA THERAPEUTICS, INC. CORPORATE PRESENTATION, FEBRUARY 2021 Exhibit 99.1 Corporate Presentation February 2021 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" wi thi n the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some |
|
| February 11, 2021 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commi |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| February 2, 2021 |
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors Exhibit 99.1 Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors NEW YORK, February 2, 2021 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. Ms. Smith brings to |
|
| January 8, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] SC 13D/A 1 e620199sc13da-pt.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 7)* Protara Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74365U107 (CUSIP Number) David Clark Elliot Pr |
|
| December 15, 2020 |
Protara Therapeutics, Inc. 1 Little West 12th Street New York, New York 10014 (646) 844-0337 December 15, 2020 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Protara Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-251224 Acceleration Request Requested Date: Friday, December |
|
| December 9, 2020 |
As filed with the Securities and Exchange Commission on December 9, 2020 Registration No. |
|
| December 8, 2020 |
Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commis |
|
| November 17, 2020 |
Protara Therapeutics, Inc. Corporate Presentation, November 2020. Exhibit 99.1 |
|
| November 17, 2020 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE PROTARA THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO PROTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. CONFIDENTIAL EXECUTION COPY Amendment to the Agreement dated June 17th, 2019 This Amendment to the Agreeme |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| October 8, 2020 |
Submission of Matters to a Vote of Security Holders - AMENDMENT NO. 1 TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissi |
|
| October 2, 2020 |
TARA / ArTara Therapeutics, Inc. / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 1, 2020 |
TARA / ArTara Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Protara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74365U 107 (CUSIP Number) September 24, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| September 25, 2020 |
TARA / ArTara Therapeutics, Inc. / Opaleye Management Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| September 23, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES 1 CONVERTIBLE NON-VOTING PREFERRED STOCK OF Protara THERAPEUTICS, INC. (pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Protara Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the provisions of th |
|
| September 23, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No.: 333-238273 PROSPECTUS SUPPLEMENT (To Prospectus dated May 26, 2020) 4,600,000 Shares Common Stock We are offering 4,600,000 shares of our common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “TARA.” On September 21, 2020, the last reported sale price of our common stock was $16.87 per share. Investing in our commo |
|
| September 23, 2020 |
Exhibit 99.2 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the prici |
|
| September 23, 2020 |
Exhibit 1.2 4,148 Shares Protara Therapeutics, Inc. Series 1 Convertible Non-Voting Preferred Stock UNDERWRITING AGREEMENT September 22, 2020 COWEN AND COMPANY, LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Dear Sirs: 1. |
|
| September 23, 2020 |
Exhibit 99.1 Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that it intends to offer and sell shares of |
|
| September 23, 2020 |
Exhibit 1.1 4,600,000 Shares Protara Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT September 22, 2020 COWEN AND COMPANY, LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Dear Sirs: 1. Introductory. Protara Therapeu |
|
| September 23, 2020 |
4,148 Shares Series Convertible 1 Preferred Stock 424B5 1 ea127224-424b5protara.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No.: 333-238273 PROSPECTUS SUPPLEMENT (To Prospectus dated May 26, 2020) 4,148 Shares Series Convertible 1 Preferred Stock We are offering 4,148 shares of our Series 1 convertible non-voting preferred stock, or the Series 1 preferred stock, which is convertible into our common stock from time to t |
|
| September 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Comm |
|
| September 22, 2020 |
As filed with the Securities and Exchange Commission on September 22, 2020 Registration No. |
|
| September 21, 2020 |
Series Convertible 1 Preferred Stock Filed Pursuant to Rule 424(b)(5) Registration No.: 333-238273 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are not offers to sell these securities, and we are no |
|
| September 21, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No.: 333-238273 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are not offers to sell these securities, and we are no |
|
| September 8, 2020 |
EX-99.1 2 ea126520ex99-1protara.htm PRESS RELEASE, DATED SEPTEMBER 8, 2020 Exhibit 99.1 Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications - Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs - - Reaches Alignment with FDA on Development P |
|
| September 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commi |
|
| September 8, 2020 |
EX-99.2 3 ea126520ex99-2protara.htm PROTARA THERAPEUTICS, INC. CORPORATE PRESENTATION, SEPTEMBER 2020 Exhibit 99.2 CorporatePresentation September2020 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" wi thin the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some c |
|
| July 31, 2020 |
Exhibit 10.1 Protara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Protara Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non- |
|
| July 31, 2020 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Julio Casoy (“Employee”) and Protara Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an Executive Employment Agreement with t |
|
| July 31, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| July 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| July 24, 2020 |
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors Exhibit 99.1 Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors NEW YORK, NY – July 24, 2020 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors. Dr. Flannelly, who current |
|
| July 16, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commissio |
|
| June 10, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36694 20-4580525 (State or other jurisdiction of incorporation) (Commission |
|
| May 21, 2020 |
Protara Therapeutics, Inc. 1 Little West 12th Street New York, New York 10014 (646) 844-0337 May 21, 2020 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Protara Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-238273 Acceleration Request Requested Date: Tuesday, May 26, 2020 |
|
| May 14, 2020 |
Exhibit 4.9 Protara Therapeutics, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Protara Therapeutics, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Protara Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and ex |
|
| May 14, 2020 |
Exhibit 4.10 PROTARA THERAPEUTICS, INC. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Protara Therapeutics, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Protara Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organi |
|
| May 14, 2020 |
As filed with the Securities and Exchange Commission on May 14, 2020 Registration No. |
|
| May 14, 2020 |
Form of Indenture, between the Company and one or more trustees to be named. EXHIBIT 4.7 PROTARA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| May 14, 2020 |
Exhibit 4.11 PROTARA THERAPEUTICS, INC. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Protara Therapeutics, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Protara Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organi |
|
| May 13, 2020 |
Certificate of Elimination of Series A Convertible Preferred Stock of ArTara Therapeutics, Inc. Exhibit 3.6 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF ARTARA THERAPEUTICS, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) ArTara Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies as follows: First: The date on which the Company’s original Certificate of Incorporation was filed with the Delaware Secret |
|
| May 13, 2020 |
Exhibit 3.3 Second CERTIFICATE OF AMENDMENT TO SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARTARA THERAPEUTICS, INC. ArTara Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: First: The name of the Corporation is ArTara Therapeutics, Inc. Second: T |
|
| May 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 23, 2020 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) ofthe Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
